HomePLX • NYSEAMERICAN
Protalix Biotherapeutics Inc
Follow
$2.54
0.97%
Pre-market:(0.00%)0.00
$2.54
Closed: Apr 2, 7:45:01 AM GMT-4 · USD · NYSEAMERICAN · Disclaimer
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | 18.22M | 73.74% |
Operating expense | 7.12M | -1.68% |
Net income | 6.49M | 207.45% |
Net profit margin | 35.65 | 161.85% |
Earnings per share | — | — |
EBITDA | 7.54M | 242.27% |
Effective tax rate | 11.24% | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 34.83M | -21.84% |
Total assets | 73.42M | -13.05% |
Total liabilities | 30.21M | -40.62% |
Total equity | 43.21M | — |
Shares outstanding | 78.03M | — |
Price to book | 4.50 | — |
Return on assets | 26.70% | — |
Return on capital | 41.50% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | 6.49M | 207.45% |
Cash from operations | 3.99M | 11.02% |
Cash from investing | -15.32M | -4,379.53% |
Cash from financing | 3.63M | — |
Net change in cash | -7.65M | -337.10% |
Free cash flow | 1.67M | -71.01% |
Previous close
$2.57
Day range
$2.50 - $2.59
Year range
$0.82 - $2.76
Market cap
198.20M USD
Avg Volume
719.38K
P/E ratio
70.22
Dividend yield
-
About
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease. Wikipedia
CEO
Founded
1993
Headquarters
Website
Employees
213
